ArticleJournal of thoracic disease2025
Transcriptome analysis and artificial intelligence for predicting lymph node metastasis of esophageal squamous cell carcinoma.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Weighted Neural Network Model Based on Laboratory Tests for Identifying Lymph Node Metastases in Esophageal Squamous Cell Carcinomas.Biosensors · 2026Article
- Accuracy of machine learning in detecting lymph node metastasis of esophageal cancer: a systematic review and meta-analysis.Translational cancer research · 2026Article
- AI-driven pathology in esophageal cancer: from early screening to precision prognostics.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node metastasis (LNM) is the most common route of metastasis in esophageal squamous cell carcinoma (ESCC), and the treatment of patients with ESCC largely depends on the LNM status. The methods for diagnosing LNM in ESCC are still not accurate enough, and accurate LNM staging is crucial for clinical practice. The purpose of this study was to investigate the value of combining transcriptome analysis with artificial intelligence (AI) in predicting LNM and to construct an effective predictive model for LNM in ESCC. Methods: We first enrolled 36 patients with ESCC for RNA sequencing (RNA-seq) to identify the differentially expressed messenger RNA (mRNAs), and then selected candidate genes via a random forest machine learning algorithm. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of three candidate genes. For the assessment of the overall survival (OS) of patients with ESCC, we used the Kaplan-Meier method and the log-rank test. Univariate and multivariate logistic regression analyses were performed to screen for risk model factors. The model was validated with the area under the curve (AUC) and visualized through a nomogram. For AI model building, random forest was conducted. We included five variables to create the AI model, and divided the data from 209 patients into a training set and a validation set to evaluate the model's performance. Thereafter, receiver operating characteristic (ROC) curves and the AUC were used to validate the AI system and to conduct subgroup analyses. Results: RNA-seq identified 2,837 genes that were differentially expressed in ESCC tissues with LNM. We used a random forest machine learning algorithm to eliminate candidate diagnostic genes for patients with ESCC with LNM, with the three most diagnostic genes being Conclusions: AI and transcriptome analysis can be used to create a risk model for predicting LNM, and it can enhance prediction accuracy and inform clinical staging and decision-making before surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.